Mark Hirschhorn Sells 35,000 Shares of Teladoc Inc (TDOC) Stock

Teladoc Inc (NYSE:TDOC) VP Mark Hirschhorn sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $80.42, for a total value of $2,814,700.00. Following the completion of the sale, the vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $804,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Mark Hirschhorn also recently made the following trade(s):

  • On Tuesday, July 10th, Mark Hirschhorn sold 20,000 shares of Teladoc stock. The stock was sold at an average price of $63.00, for a total value of $1,260,000.00.

Shares of NYSE:TDOC traded up $3.95 during trading on Thursday, hitting $82.50. The stock had a trading volume of 1,692,800 shares, compared to its average volume of 1,202,496. Teladoc Inc has a 12-month low of $27.30 and a 12-month high of $83.75. The stock has a market cap of $5.62 billion, a price-to-earnings ratio of -50.55 and a beta of 0.58. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.58.

Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.01. Teladoc had a negative return on equity of 19.10% and a negative net margin of 37.78%. The firm had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $91.56 million. During the same period last year, the business posted ($0.28) earnings per share. The company’s revenue for the quarter was up 112.1% compared to the same quarter last year. equities analysts anticipate that Teladoc Inc will post -1.51 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Teladoc by 9.0% in the second quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock worth $308,759,000 after purchasing an additional 437,136 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Teladoc by 1.4% in the first quarter. JPMorgan Chase & Co. now owns 4,678,836 shares of the health services provider’s stock worth $188,559,000 after purchasing an additional 65,383 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Teladoc by 82.8% in the second quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock worth $109,318,000 after purchasing an additional 853,076 shares during the last quarter. Zevenbergen Capital Investments LLC raised its stake in shares of Teladoc by 3.9% in the second quarter. Zevenbergen Capital Investments LLC now owns 1,629,170 shares of the health services provider’s stock worth $94,574,000 after purchasing an additional 61,325 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its stake in shares of Teladoc by 6.0% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,477,276 shares of the health services provider’s stock worth $85,756,000 after purchasing an additional 83,319 shares during the last quarter.

TDOC has been the subject of several recent analyst reports. Jefferies Financial Group set a $74.00 price target on Teladoc and gave the stock a “buy” rating in a report on Wednesday, July 11th. Citigroup raised their price target on Teladoc to $62.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. SunTrust Banks raised their price target on Teladoc from $48.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. Canaccord Genuity raised their price target on Teladoc from $47.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, June 5th. Finally, Craig Hallum raised Teladoc from a “hold” rating to a “buy” rating in a report on Tuesday, June 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Teladoc currently has a consensus rating of “Buy” and an average target price of $67.80.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: Earnings Per Share

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply